The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis | Zendy

Matthew WarrenderSparkes | Zendy; Tim Spelman | Zendy; Guillermo Izquierdo | Zendy; Maria Trojano | Zendy; Alessandra Lugaresi | Zendy; François Grand’Maison | Zendy; Eva Havrdová | Zendy; Dana Horáková | Zendy; Cavit Boz | Zendy; Celia OrejaGuevara | Zendy; Raed Alroughani | Zendy; Gerardo Iuliano | Zendy; Pierre Duquette | Zendy; Marc Girard | Zendy; Murat Terzi | Zendy; Raymond Hupperts | Zendy; Pierre Grammond | Zendy; Thor Petersen | Zendy; Ricardo FernándezBolaños | Zendy; Marcela Fiol | Zendy; Eugenio Pucci | Zendy; Jeannette LechnerScott | Zendy; Freek Verheul | Zendy; Edgardo Cristiano | Zendy; Vincent Van Pesch | Zendy; Tatjana PetkovskaBoskova | Zendy; Fraser Moore | Zendy; Ilya Kister | Zendy; Roberto Bergamaschi | Zendy; María Laura Saladino | Zendy; Mark Slee | Zendy; Michael Barnett | Zendy; Maria Pia Amato | Zendy; Cameron Shaw | Zendy; Neil Shuey | Zendy; Carolyn Young | Zendy; Orla Gray | Zendy; Ludwig Kappos | Zendy; Helmut Butzkueven | Zendy; Tomáš Kalinčík | Zendy; Vilija Jokubaitis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

Author(s) -

Matthew WarrenderSparkes,

Tim Spelman,

Guillermo Izquierdo,

Maria Trojano,

Alessandra Lugaresi,

François Grand’Maison,

Eva Havrdová,

Dana Horáková,

Cavit Boz,

Celia OrejaGuevara,

Raed Alroughani,

Gerardo Iuliano,

Pierre Duquette,

Marc Girard,

Murat Terzi,

Raymond Hupperts,

Pierre Grammond,

Thor Petersen,

Ricardo FernándezBolaños,

Marcela Fiol,

Eugenio Pucci,

Jeannette LechnerScott,

Freek Verheul,

Edgardo Cristiano,

Vincent Van Pesch,

Tatjana PetkovskaBoskova,

Fraser Moore,

Ilya Kister,

Roberto Bergamaschi,

María Laura Saladino,

Mark Slee,

Michael Barnett,

Maria Pia Amato,

Cameron Shaw,

Neil Shuey,

Carolyn Young,

Orla Gray,

Ludwig Kappos,

Helmut Butzkueven,

Tomáš Kalinčík,

Vilija Jokubaitis

Publication year - 2015

Publication title -

multiple sclerosis journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.729

H-Index - 131

eISSN - 1477-0970

pISSN - 1352-4585

DOI - 10.1177/1352458515594041

Subject(s) - fingolimod , medicine , discontinuation , multiple sclerosis , hazard ratio , persistence (discontinuity) , expanded disability status scale , natalizumab , observational study , physical therapy , confidence interval , immunology , geotechnical engineering , engineering

We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research